SCHEMBL17112792

SCHEMBL17112792

COc1ccc(COc2ccc(C=C(C#N)C(=O)O)cc2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.64
MAPT P10636 5/20 0.64
NPC1 O15118 3/20 0.64
RAB9A P51151 3/20 0.64
GAA P10253 1/20 0.64
KMT2A Q03164 6/20 0.59
MEN1 O00255 5/20 0.59
TDP1 Q9NUW8 4/20 0.59
CTDSP1 Q9GZU7 3/20 0.56
APOBEC3A P31941 1/20 0.56
APOBEC3G Q9HC16 1/20 0.56
HPGD P15428 3/20 0.55
ALDH1A1 P00352 3/20 0.55
CISD1 Q9NZ45 1/20 0.55
SLC16A3 O15427 1/20 0.55
CYP3A4 P08684 1/20 0.55
SLC16A1 P53985 1/20 0.55
GPR35 Q9HC97 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
POLB P06746 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17112791 1.00 KDM4E (0.64) KDM4EMAPTNPC1RAB9AGAA
SCHEMBL28237091 0.88 KDM4E (0.81) KDM4EMAPTNPC1RAB9AGAA
SCHEMBL24845094 0.88 KDM4E (0.81) KDM4EMAPTNPC1RAB9AGAA
SCHEMBL4968638 0.88 ALDH1A1 (0.65) KDM4EMAPTHPGDALDH1A1CISD1
SCHEMBL782091 0.88 ALDH1A1 (0.65) KDM4EMAPTHPGDALDH1A1CISD1
SCHEMBL782092 0.88 ALDH1A1 (0.65) KDM4EMAPTHPGDALDH1A1CISD1
SCHEMBL13060223 0.86 KDM4E (0.55) KDM4EMAPTNPC1RAB9AGAA
SCHEMBL19011313 0.85 ALDH1A1 (0.59) KDM4EMAPTNPC1RAB9AGAA
SCHEMBL13060225 0.85 KDM4E (0.57) KDM4EMAPTNPC1RAB9AGAA
SCHEMBL21637629 0.84 ALDH1A1 (0.59) KDM4EMAPTHPGDALDH1A1CISD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10280170-B2 Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2019-05-07 US disclosed
EP-3129376-B1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-A][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-12-26 EP disclosed
US-20170174690-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-06-22 US disclosed
EP-3129376-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-A][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2017-02-15 EP disclosed
WO-2015144799-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10280170-B2 Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors ROS1, NOX1, NOX5 KDM4E 2607/4885MAPT 1425/4885NPC1 835/4885
US-20170174690-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS ROS1, NOX1, NOX5 KDM4E 2607/4885MAPT 1425/4885NPC1 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.